Ligand Pharma (LGND) Tops Q2 EPS by 10c; Affirms FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Roth Capital Says to Buy Ligand Pharma (LGND) on Today's 'Bad' Downgrade
August 5, 2016 11:27 AM EDTRoth Capital affirms Ligand Pharma (Nasdaq: LGND) at Buy with a price target of $149 following Deutsche Bank's downgrade to Sell on the stock today.
Analyst Joseph Pantginis commented today, Our ongoing thesis for Ligand has been one of accumulation over the long term and believe today's weakness offers an opportunity for just that. There has been no call, to date, by the competitor... More
Deutsche Bank Downgrades Ligand Pharma (LGND) to Sell
August 5, 2016 6:45 AM EDTDeutsche Bank downgraded Ligand Pharma (NASDAQ: LGND) from Hold to Sell with a price target of $110.00 (from $104.00). The downgrade was tied to valuation.
Analyst Gregg Gilbert said, "Our model and $110 target factor in continued growth for key royalty drivers (particularly AMGNs Kyprolis and Novartis Promacta), growth in technology deals (tied to Captisol and other platforms), and launches of new... More
